Bachem webinar on avoiding epimerization in peptide synthesis

Bubendorf, Switzerland: – Bachem, the leading CDMO for peptides and oligonucleotides manufacturing, is to host a webinar to explore solutions to the epimerization that can cause problems in peptide synthesis.

Epimerization is the stereochemistry phenomenon in which there is a change in the configuration of a single chiral center to form a diastereomer. This is an often-underestimated problem in the synthesis of C-terminal cysteine (Cys) peptide acids that can cause unwanted side reactions spoiling the process.

Epimerization solutions

Bachem’s free to register online webinar ‘Avoiding epimerization in peptide synthesis’ will be held on Wednesday, February 21, 2024, commencing at 1700 hrs. CET (UTC +1) and lasting approximately one hour.

The session will discuss the importance of synthesizing Cys as a key amino acid in many therapeutic peptides, with its residues involved in the formation of the key amide and disulfide peptide bonds, and in thioether formation for peptide cyclization.

It will also show how and why Cys is especially sensitive to the occurrence of epimerization-related side reactions during solid-phase peptide synthesis (SPPS).

The webinar will then go on to discuss recent Bachem research efforts to minimize these side reactions associated with Cys.

Organic chemistry experts

The webinar will feature contributions and scientific insights from three experts in the field of organic chemistry: Chris McGee and Ralph Schönleber from Bachem, along with Prof. Fernando Albericio, Editor of the International Journal of Peptide Research and Therapeutics.

• Dr. Chris McGee is Bachem’s Vice President & Head of Global Business Development and has been at the forefront of communications related to the development and manufacturing of new peptide and oligonucleotide-based chemical entities with his team of peptide expert.
• Dr. Ralph Schönleber is Vice President R&D at Bachem and heads its Process Research Department. As a member of Bachem’s International Research Committee, Ralph has played an influential role in Bachem’s entry into oligonucleotide business.
• Dr. Fernando Albericio is a Professor at the University of KwaZulu-Natal and currently edits the International Journal of Peptide Research and Therapeutics. He is a Councilor of the American Peptide Society (APS), which recently honored him with its Vincent du Vigneaud Award. He has also been awarded the Doctorate Honoris Causa by the Universidad de Buenos Aires (Argentina).

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.

Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

For further information, see www.bachem.com.

Resources

Click on Bachem webinar ‘Avoiding epimerization in peptide synthesis’  to register for the event.
Click on Bachems News to see latest News & Events.